ライフサイエンスコーパス: muramyl dipeptide

1 e recognition of bacterial cell wall-derived muramyl dipeptide.

2 n of the IL-1 receptor plus the co-stimulant muramyl dipeptide.

3 pon treatment of cells with the NOD2 ligand, muramyl dipeptide.

4 fibroblasts show an increased sensitivity to muramyl dipeptide.

5 owing NOD2-mediated recognition of bacterial muramyl dipeptide.

6 sease were deficient in their recognition of muramyl dipeptide.

7 d to lipopolysaccharide but not to synthetic muramyl dipeptide.

8 NOD2 is able to sense muramyl dipeptide, a specific bacterial cell wall compon

9 tive bacterial cell wall, while NOD2 detects muramyl dipeptide, a ubiquitous cell wall peptidoglycan

10 step mechanism, requiring microbial product, muramyl-dipeptide, a component of peptidoglycan, followe

11 gh its WD-40 domain, binds to NOD2 following muramyl dipeptide activation.

12 ecular mechanisms that underlie detection of muramyl dipeptide and assembly of NOD2-containing signal

13 ombinant protein is able to bind directly to muramyl dipeptide and can associate with known NOD2-inte

14 39iCstop) are impaired in the recognition of muramyl dipeptide and Enterococcus faecalis, a commensal

15 Binding of NOD2 to muramyl dipeptide and homo-oligomerization of NOD2 are e

16 However, agonists of NOD2, such as muramyl dipeptide and lysine-containing muramyl tripepti

17 , no significant binding was evident between muramyl dipeptide and NOD1.

18 binding of nucleotide followed by binding of muramyl dipeptide and oligomerization of NOD2 into a sig

19 polymeric form rather than monomers such as muramyl dipeptide and require PGN lysosomal hydrolysis t

20 onstrate that peptidoglycan monomers such as muramyl dipeptide and soluble peptidoglycan fail to indu

21 of a specific bacterial cell wall component, muramyl dipeptide, and activation of Nod2 stimulates an

22 uding lipopolysaccharide, lipoteichoic acid, muramyl dipeptide, and heat shock proteins.

23 s anthracis lethal toxin, Toxoplasma gondii, muramyl dipeptide, and host intracellular ATP depletion.

24 hypophagic agents, lipopolysaccharide (LPS), muramyl dipeptide, and interleukin-1, when challenged on

25 nges induced by the specific Nod2 activator, muramyl dipeptide, and that the role of NIK occurs in se

26 Muramyl dipeptides as well as the major muramyl tetrapep

27 promiscuous T-cell epitope (ie, MVF) and nor-muramyl-dipeptide as adjuvant emulsified in SEPPIC ISA 7

28 in-containing protein 2 (NOD2) by its ligand muramyl dipeptide, as compared to activation via heterod

29 TZ-injected WT mice received the NOD2 ligand muramyl dipeptide, both hyperglycemia and the proinflamm

30 rose-immobilized muramyl dipeptide or GlcNAc-muramyl dipeptide but not to PGN pentapeptide.

31 idoglycan (PGN), a TLR2 ligand that contains muramyl dipeptide, but not other TLR ligands; in contras

32 ptidoglycan are mediated by detection of its muramyl dipeptide component in the cytosol by NOD2, we r

33 lthough Zn(2+) is required for hydrolysis of muramyl dipeptide, disulfide oxidation is not required f

34 lysaccharide, lipoteichoic acid, lipid A and muramyl dipeptide elicit cryptdin secretion.

35 caspase recruitment domain (CARD) 15 detects muramyl dipeptide from bacterial peptidoglycans and medi

36 ignal transduction properties in response to muramyl dipeptide in cellular assays.

37 ctivation after the recognition of bacterial muramyl dipeptide in intestinal epithelial cells.

38 Costimulation of monocytes with LPS and muramyl dipeptide induced an enhanced IL-6 response that

39 both RIP2 tyrosine phosphorylation and MDP (muramyl dipeptide)-induced cytokine release in a variety

40 The dominant negative form of TAK1 abolished muramyl dipeptide-induced NF-kappaB activation in Nod2-e

41 s attenuates heightened ITCH(-/-) macrophage muramyl dipeptide-induced responses.

42 Its activation by bacterial muramyl dipeptide induces expression of proinflammatory

43 ty mediated by Nod2 recognition of bacterial muramyl dipeptide is abolished in Nod2-deficient mice.

44 NOD2-dependent recognition of S. aureus and muramyl dipeptide is facilitated by alpha-toxin (alpha-h

45 Because muramyl dipeptide is the essential structure of peptidog

46 Bacterial proteoglycan-derived muramyl dipeptide (MDP) activates the intracellular NOD2

47 ty is based on previous studies showing that muramyl dipeptide (MDP) activation of NOD2 negatively re

48 ffectiveness of lipopolysaccharide (LPS) and muramyl dipeptide (MDP) administered into the brain to i

49 n-2 (NOD2) receptor detects bacteria-derived muramyl dipeptide (MDP) and activates the transcription

50 transports small bacterial peptides, such as muramyl dipeptide (MDP) and l-Ala-gamma-D-Glu-meso-diami

51 nts of bacterial peptidoglycan (PGN), namely muramyl dipeptide (MDP) and muramyl tripeptide (MTP).

52 ogenic bacterial cell wall (BCW) components, muramyl dipeptide (MDP) and peptidoglycan (PG).

53 ands similar to the minimal synthetic ligand muramyl dipeptide (MDP) are generated by internalization

54 ling and autophagy activation in response to muramyl dipeptide (MDP) by immunoblot, confocal microsco

55 NOD2 recognizes muramyl dipeptide (MDP) derived from bacterial peptidogl

56 R4 and Nod2 signaling by exposure to LPS and muramyl dipeptide (MDP) exhibit impaired TNF-alpha and I

57 (P.g.)-induced TNF-alpha can be affected by muramyl dipeptide (MDP) in a biphasic concentration-depe

58 show that activation of Nod2 by its ligand, muramyl dipeptide (MDP) in the bacterial cell wall, indu

59 ase in response to the presence of bacterial muramyl dipeptide (MDP) in the host cell cytoplasm, ther

60 Muramyl dipeptide (MDP) is a peptidoglycan moiety derive

61 he synergistic effect of IL-32 and synthetic muramyl dipeptide (MDP) on cytokine production was absen

62 ria produce an unusual, glycolylated form of muramyl dipeptide (MDP) that is more potent and efficaci

63 LR), is an intracellular sensor of bacterial muramyl dipeptide (MDP) that was suggested to promote se

64 contrast, ApoE(-/-) mice injected i.p. with Muramyl DiPeptide (MDP) to stimulate NOD2 and given an o

65 Here we investigated the effects of muramyl dipeptide (MDP), a bacterial cell wall component

66 n important role in innate immunity to sense muramyl dipeptide (MDP), a component of bacterial cell w

67 n of primary monocyte-derived macrophages by muramyl dipeptide (MDP), a component of bacterial peptid

68 receptor, induces autophagy on detection of muramyl dipeptide (MDP), a component of microbial cell w

69 We found that pretreatment with muramyl dipeptide (MDP), a ligand for Nod2, significantl

70 orm of mycobacterial cell wall component and muramyl dipeptide (MDP), a peptidoglycan derivative resp

71 Muramyl dipeptide (MDP), a product of bacterial cell-wal

72 quently, we determined that the NOD2 ligand, muramyl dipeptide (MDP), activates NF-kappaB in primary

73 Nod2 is required for an immune response to muramyl dipeptide (MDP), an immunostimulatory fragment o

74 components, such as the NOD2 cognate ligand muramyl dipeptide (MDP), and are selectively required fo

75 an intracellular sensor of bacteria-derived muramyl dipeptide (MDP), increase susceptibility to Croh

76 ciated molecular patterns (PAMPs), including muramyl dipeptide (MDP), LPS, and a B-class CpG oligonuc

77 ls were given an intraarticular injection of muramyl dipeptide (MDP), peptidoglycan (PG; a metabolite

78 nse of peripheral blood mononuclear cells to muramyl dipeptide (MDP), the ligand for NOD2.

79 Muramyl dipeptide (MDP), the microbial activator of nucl

80 ion in primary human mononuclear cells, with muramyl dipeptide (MDP), the minimal NOD2/CARD15 activat

81 Muramyl dipeptide (MDP), the NOD2 agonist, induces NF-ka

82 One such receptor, NOD2, via recognition of muramyl dipeptide (MDP), triggers a distinct network of

83 whole-genome level by microarray analysis of muramyl dipeptide (MDP)-treated Itch(-/-) primary macrop

84 r of a component of the bacterial cell wall, muramyl dipeptide (MDP).

85 r 2, which recognizes the bacterial derivate muramyl dipeptide (MDP).

86 duction in response to i.p. and intravitreal muramyl dipeptide (MDP).

87 aspase-1, which responds to bacterial ligand muramyl-dipeptide (MDP).

88 e NOD1 ligand MurNAcTri(DAP) and NOD2 ligand muramyl dipeptide [MDP]) but not bacterial Toll-like rec

89 In contrast, muramyl dipeptide-mediated inflammasome formation is not

90 ochemical and functional analyses identified muramyl dipeptide (MurNAc-L-Ala-D-isoGln) derived from p

91 so specifically bound to agarose-immobilized muramyl dipeptide or GlcNAc-muramyl dipeptide but not to

92 eveloped tolerance to repeated injections of muramyl dipeptide or LPS and were cross-tolerant to S-O-

93 (a metabolite of which is the NOD2 agonist, muramyl dipeptide), or synthetic TLR2/1 and TLR2/6 agoni

94 hole-blood stimulation with the NOD2 ligand, muramyl dipeptide, or B. pseudomallei.

95 amma-d-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively).

96 of the peptidoglycan fragments meso-DAP and muramyl dipeptide, respectively, and drive the activatio

97 amma-d-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, respectively.

98 with ZNRF4 under either 55 unstimulated and muramyl dipeptide-stimulated conditions.

99 and Nod2(-/-) macrophages were refractory to muramyl dipeptide stimulation.

100 Stimulation of macrophages with muramyl dipeptide, the Nod2 activator, enhanced immune r

101 soGln for L-isoGln eliminated the ability of muramyl dipeptide to stimulate NOD2, indicating stereose

102 hogen-free facility, were given antibiotics, muramyl dipeptide (to stimulate NOD2), or dextran sodium

103 Muramyl dipeptide was recognized by NOD2 but not by TLR2

104 )CSK(4), a TLR2 ligand that does not contain muramyl dipeptide, were normal.